Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of nab-paclitaxel + ifosfamide + cisplatin in pediatric recurrent or refractory extracranial germ cell tumors
ChiCTR2000038919Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, ifosfamide and cisplatin in germ cell tumor (GCT), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Nov 2020; status: recruiting.
02
Drugs
paclitaxelifosfamidecisplatin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on ChiCTR2000038919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038919.